![]() |
|
|

Departamentos de Fisiología de la Nutrición,
* Endocrinología y Metabolismo, y
Patología Experimental, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán," Mexico City, Mexico
2To whom correspondence should be addressed. E-mail: artovar{at}quetzal.innsz.mx.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: soy protein sterol-regulatory element binding protein-1 fatty liver insulin
Several studies in humans (1) and animals (2) have established that the ingestion of a soy protein diet reduces serum cholesterol and triglycerides, particularly in hypercholesterolemic subjects (3) although controversy exists concerning its efficacy (4). Soy protein alone or as a major source of protein in a diet containing adequate levels of energy and other essential nutrients promotes adequate growth in infants (5). The nutritional value of soy protein in young children is essentially equivalent to that of milk protein (6). The nutritional quality of soy protein in nitrogen balance studies in adults showed
83% of the value of egg protein and an equal value for milk protein (5). However, the molecular mechanism by which soy protein decreases serum lipids has not been fully established. Several possible mechanisms have been proposed (7), including enhancement of bile acid excretion, changes in the insulin:glucagon ratio, thyroid hormone concentrations, and an amino acid composition that causes changes in cholesterol metabolism.
Hepatic lipid metabolism is controlled in part by the transcription factors termed sterol regulatory element binding proteins (SREBPs)3 (8,9). These transcription factors belong to the basic helix-loop-helix-leucine zipper family (10,11). There are 3 isoforms of SREBPs that are membrane-bound to the endoplasmic reticulum and nuclear envelope, i.e., SREBP-1a, SREBP-1c, and SREBP-2. The NH2-terminal domain of the mature forms of these transcription factors is released after 2 proteolytic cleavages in the Golgi apparatus by 2 specific proteases, SP1 and SP2. The NH2-terminal of SREBPs travels into the nucleus and binds to the cis-acting element termed the sterol regulatory element in the promoter or enhancer regions of genes involved in cholesterol or fatty acid synthesis. In the liver, SREBP-1c and SREBP-2 are the predominant forms (12). SREBP-2 preferentially stimulates transcription of the genes of cholesterol synthesis, including hydroxymethylglutaryl-CoA (HMG-CoA) reductase and HMG-CoA synthase (13), whereas SREBP-1c stimulates transcription of the genes of fatty acid biosynthesis (14), such as acetyl CoA carboxylase and fatty acid synthase (FAS). SREBP-2 is activated in response to a low cholesterol content of the cell, and SREBP-1c by insulin (15). In both instances, activation is mediated through the SREBP cleavage-activating protein (16).
It is not known whether the consumption of a soy protein diet regulates cholesterol and fatty acid synthesis through SREBPs. Recent evidence exists that rats fed a soy protein diet have reduced SREBP-1 expression (17). Furthermore, we demonstrated that after 1 h of casein diet consumption, serum insulin concentration increases 3.5-fold over the basal levels, whereas ingestion of a soy protein diet increases serum insulin by only 50% (18). Recent evidence indicates that ingestion of a high-isoflavone soy protein diet improves insulin resistance in obese Zucker rats, and it was suggested that part of the beneficial effects are mediated by peroxisome-proliferator activated receptors (19). On the other hand, it was demonstrated that insulin selectively stimulates SREBP-1 expression in liver (15). Therefore, if consumption of soy protein maintains serum insulin concentration in the low-normal range, we can speculate that soy protein may not stimulate fatty acid synthesis in liver. Thus, the purpose of the present work was to study the short- and long-term effects of the consumption of a soy protein diet on serum insulin, and serum and hepatic lipid concentrations, and its association with the hepatic mRNA concentrations of SREBP-1, FAS, and malic enzyme. Reduction in the expression of lipogenic genes in the liver may prevent the development of steatosis.
| MATERIALS AND METHODS |
|---|
|
|
|---|
22°C with a 12-h light:dark cycle and free access to water. To synchronize food intake, rats were trained to consume the experimental diets during a restricted period of 7 h (09001600 h) for 10 d. The diets contained 18 g casein or 18 g soy protein/100 g (Control diets; Table 1). On d 10, 5 rats from each group previously anesthetized with CO2 were killed by decapitation at 0, 30, 60, 90, and 120 min after they started to eat their meal. The liver sample used for RNA preparation was removed rapidly, frozen immediately in liquid nitrogen, and stored at -80°C. Blood samples were obtained and serum was separated and frozen at -20°C to measure serum insulin and glucagon concentrations.
|
Isolation of nuclear extracts. Nuclear extracts from liver of rats fed only soy protein or casein were obtained by centrifugation in a sucrose gradient as described by Sheng et al. (20). Tissue was homogenized with a teflon pestle in lysis buffer (4 g tissue/30 mL) containing 0.3 mol/L sucrose, 5 mmol/L dithiothreitol (DTT), 5 mmol/L MgCl2, 0.05% Triton X-100, and 10 mmol/L Tris/HCl, pH 7.5. A cocktail of protease inhibitors containing 5 mmol/L benzamidine, 1 mmol/L diisopropyl fluorophosphate, 1 mmol/L EDTA, 1 mmol/L EGTA, and 1 mmol/L leupeptin, was added to the lysis buffer. Tissue homogenates were centrifuged at 800 x g for 10 min at 4°C. The supernatant was discarded and the pellet was resuspended in 20 mL of sucrose buffer containing 2.3 mol/L sucrose, 2 mmol/L MgCl2, and 10 mmol/L Tris/HCl, pH 7.5, with the same cocktail of protease inhibitors. The suspension was layered in Quick seal tubes onto 10 mL of sucrose buffer. Tubes were centrifuged at 100,000 x g for 45 min at 4°C. The pellet containing nuclei was resuspended in 500 µL of storage buffer containing 50% glycerol, 2 mmol/L MgCl2, 0.1 mmol/L EDTA, and 50 mmol/L HEPES, pH 7.5. Nuclei were stored at -70°C until analysis. The protein concentration of the nuclear extracts was determined by the Lowry assay (21).
Immunoblot analysis of SREBP-1 in nuclear extracts. Nuclear extracts (20 µg) were separated by SDS-PAGE in 8% gels according to Laemmli (22). Before electrophoresis, all samples were boiled for 2 min in the presence of 1% SDS, with 0.2 mol/L DTT. For immunoblotting, proteins in the SDS-PAGE gel were transferred to polyvinylidene difluoride (PVDF) membranes (Boehringer Mannheim) using a Transphor electrophoresis unit (Hoefer Scientific Instruments). The PVDF membranes were blocked with 40 g/L powdered skim milk overnight at room temperature, and immunoblotting was performed using a monoclonal antibody against SREBP-1 overnight at 4°C. The monoclonal antibody anti-SREBP-1 was obtained from the hybridoma of ATCC (CRL-2121). Immunoreactive protein bands were visualized using horseradish peroxidase-labeled goat anti-mouse antibody (1:6000) after the oxidation of luminol as luminescent substrate. Light emission was detected by exposure to autoradiography film (ECL, Amersham Life Science).
Northern blot analysis.
Total liver RNA was isolated from liver according to Chomczynski and Sacchi (23). The abundance of malic enzyme, HMG-CoA reductase, LDL receptor, fatty acid synthase (FAS), and SREBP-1 mRNA was determined by Northern blot analysis. RNA (20 µg) was electrophoresed in a 1% agarose gel containing 18% formaldehyde, transferred to a nylon membrane filter (Hybond-N+), and cross-linked with a UV crosslinker (Amersham). Probes were obtained by RT-PCR using primers described in Table 2. PCR products were purified with the high pure PCR product purification kit (Roche) and labeled with Redivue [
-32P] dCTP (110 TBq/mmol) using the Rediprime DNA labeling kit (Amersham). Membranes were prehybridized with rapid-hyb buffer (Amersham) at 65°C for 1 h, and then hybridized with the cDNA probe (53.3 MBq/L) for 2.5 h at 65°C. Membranes were washed once with 2X SSC (1X SSC = 0.15 mol/L sodium chloride,15 mol/L sodium citrate containing 0.1% SDS) at room temperature for 20 min and then twice for 15 min with 0.1X SSC containing 0.1% SDS at 65°C. Digitization of the images and quantitation of the radioactivity of the bands were done using the Instant Imager (Packard Instrument). Membranes were also exposed to Extascan film (Kodak) at -70°C with an intensifying screen.
|
Liver lipids. Total lipids were extracted according to the method of Folch et al. (24), and triglycerides and cholesterol concentrations were assayed as described above.
Oil red O staining for lipids in rat liver. Tissues were sliced (4 µm) and stained in 60% of the oil red O stock solution (0.5 g oil red O in 100 mL isopropanol) for 30 min. Tissues were briefly washed in 60% isopropanol and then rinsed in distilled water for microscopic observation and photography.
Malic enzyme activity. Liver (1 g) was homogenized according to Haney et al. (25) in 5 volumes of iced buffer containing 250 mmol/L sucrose, 10 mmol/L Tris HCl, 1 mmol/L mercaptoethanol, pH 7.4, and centrifuged at 100,000 x g, for 1 h at 4°C. The clear supernatants were used to measure enzyme activity. Liver malic enzyme activity was assayed by measuring NADPH formation from L-malate in a spectrophotometer at 340 nm and 26°C according to Hsu and Lardy (26). A unit of activity was defined as 1 µmol of NAPDH formed/min at 26°C. Malic enzyme activity was expressed as mU/mg protein. Protein concentration of the clear supernatants was determined by the Lowry assay (21).
Statistical analysis. Results are presented as means ± SEM, n = 5. Results of Expt. 1 were assessed by 1-way repeated-measures ANOVA, and results of Expt. 2 were assessed by 2-way ANOVA with type of protein and fat content in the diet as independent variables. Significant differences between groups were determined by Fishers protected least-square difference test). Associations between variables were tested using the Spearman rank correlation test. P-values < 0.05 were accepted as significant (Statview, V.4.5, Abacus Concepts).
| RESULTS |
|---|
|
|
|---|
Time course response of serum insulin in rats fed soy protein or casein diet.
Serum insulin concentration in food-deprived rats did not differ between groups. The casein diet, as expected, increased insulin concentration rapidly compared with rats fed the soy protein diet. Thus on d 10, rats fed the casein diet had 5.3-, 6.5-, and 6.7-fold higher serum insulin concentration with respect to food-deprived levels 30, 60, and 90 min after food consumption, respectively. Rats fed the soy protein diet had 1.4-, 1.9-, and 1.9-fold higher serum insulin concentration with respect to food-deprived levels at the same time points (P < 0.05). Rats fed the soy protein diet had
36% less serum insulin than rats fed the casein diet. Two hours after consumption of the respective diets, serum insulin concentrations did not differ between the groups (Fig. 1a).
|
Expt. 2. Effect of long-term soy protein consumption
Weight gain, food intake, and serum glucose and leptin concentrations of rats. Long-term consumption of the soy protein or casein diets from d 21 to 120 of the study did not affect weight gain (data not shown). However, after consumption of the four experimental diets for 30 d, only rats fed soy protein HF or casein HF diets had significant weight gains (79 and 103%, respectively) compared with their respective control groups (Table 3). Feed intakes and serum glucose concentrations did not differ among the groups (Table 3). Rats fed the high-fat soy protein diet had greater serum leptin levels than rats fed the soy control diet (P < 0.001), whereas rats fed the casein control or casein HF diets had serum leptin concentrations that did not differ. The final body weight of all rats studied was significantly correlated with their serum leptin concentrations (Fig. 2).
|
|
68% compared with rats fed the casein or casein HF diets, respectively. The fat content in the soy protein diets did not alter the capacity of this protein to reduce serum cholesterol levels compared with the respective groups fed the control or HF casein diets (Table 3). Rats fed the soy or soy HF diets had serum cholesterol that was 21 and 24% lower compared with rats fed the casein and casein HF diets, respectively (P < 0.01). Histological studies. Consumption of the casein diet increased the number and size of lipid vacuoles. Rats fed the casein or casein HF diets had an increase in the number of oil droplets in the liver (Fig. 3Aand 3C) compared with rats fed the soy protein or soy protein HF diets (Fig. 3B and 3D).
|
57% lower than that in rats fed the casein or casein HF diets. Serum insulin and glucagon. Rats fed the casein or casein HF diets for 30 d developed hyperinsulinemia. Rats fed the soy protein or soy protein HF diets had 65 and 45% lower serum insulin concentrations than rats fed the casein or casein HF diets (P < 0.001) (Table 3). Interestingly, serum glucagon had a similar response, i.e., rats fed the casein or casein HF diets had the highest concentrations of this hormone. Serum glucagon concentrations were 44 and 39% lower in rats fed the soy protein or soy protein HF diets, respectively, than in rats fed the casein or casein HF diets (P < 0.001) (Table 3). Thus, the increase in insulin in rats fed the casein or casein HF diets could trigger the lipogenesis. The insulin:glucagon ratio tended to be higher (P = 0.08) in rats fed the casein diets than in rats fed the soy protein diets (Table 3).
mRNA concentrations of hepatic genes of lipid metabolism.
Rats fed the casein or casein HF diets had higher SREBP-1 mRNA concentrations than rats fed the soy protein or soy protein HF diets (Figs. 4, 5). The increment in SREBP-1 was associated with an increase in FAS and malic enzyme mRNA in rats fed casein, whereas a low abundance of SREBP-1, as observed in rats fed the soy protein diets, was accompanied by anextremely low abundance of FAS and malic enzyme mRNAs. On the other hand, there were greater increases in HMG-CoA reductase and LDL receptor mRNA concentration in rats fed the soy protein diets than in rats fed the casein diets. Because cholesterol is eliminated from the body primarily as bile acids, and the limiting step for the synthesis of bile acids is catalyzed by the enzyme 7-
hydroxylase (CYP7A1), mRNA concentration of this enzyme was measured in control rats fed the casein or soy protein diet. Rats fed the soy protein diets had significantly higher CYP7A1 mRNA expression than rats fed the casein diets (Figs. 4, 5).
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Insulin has been shown to play a key role in the regulation of the expression of SREBP-1 (27). Studies with obese mice or with a transgenic mouse model that resembles generalized lipodystrophy in humans (28) showed that elevated SREBP-1c levels are associated with hyperinsulinemia (29), whereas the disruption of SREBP-1 in mice reduces the expression of lipogenic enzymes, as well as the triglycerides content in liver (30). Interestingly, our data showed that SREBP-1 mRNA expression increased rapidly after the short-term consumption of a casein or soy protein diet (Fig. 1b). The casein diet stimulated postprandial serum insulin levels to a greater extent than did soy protein, leading to a higher expression of SREBP-1 mRNA. It is important to emphasize that the modulation of serum insulin and SREBP-1 abundance depended of the type of protein consumed in the short-term study (Expt. 1) because the diets differed only in the type of protein.
On the other hand, we observed that rats fed the casein HF diet had less induction of lipogenic genes than control rats fed casein even though both groups had high serum insulin concentrations, and also high serum and hepatic triglycerides. Our results agree with previous findings showing that consumption of a high-fat diet reduces lipogenesis (31). Furthermore, there is evidence that not only PUFA, but also SFA decrease the rate of fatty acid synthesis in Caco-2 cells; this repression is accompanied by a decrease in the expression of SREBP-1 and FAS (32). Therefore, the long-term consumption of a HF diet reduces lipogenesis, although it does not prevent the accumulation of lipids of dietary origin.
The accumulation of triglycerides in nonadipose cells is associated with lipotoxicity (33). In genetically obese Zucker diabetic fatty rats, there is an increase of triglycerides in skeletal muscle, heart, pancreatic ß-cells, and liver (34). The excessive energy intake by these rats due to the absence of the leptin receptor does not allow nonadipose tissue to oxidize the fatty acid excess through the stimulation of PPAR-
by leptin (35). High energy intake results in elevated serum insulin levels that induce SREBP-1 expression, leading to an accelerated lipogenesis in nonadipose tissues (15,27). The consequence of all these alterations is the development of the metabolic syndrome X (36). In our study, we observed that long-term consumption of a soy protein diet prevented an increase in lipid depots, mainly triglycerides, in the liver. Thus, ingestion of this protein might slow the progress of insulin resistance, whereas consumption of casein can cause fatty liver, hypertriglyceridemia, and hyperinsulinemia, factors that may lead to the development of insulin resistance and diabetes.
It has been shown that during peripheral insulin resistance, there is a concomitant increase in serum insulin and glucagon (37). In rats fed the casein or casein HF diet, we observed that the insulin:glucagon ratio tended to be higher than in rats fed the soy protein diets. Thus, our results may support the hypothesis that long-term consumption of a casein diet allows the development of insulin resistance independently of the fat content of the diet. We are conducting studies with euglycemic clamps to test this hypothesis.
At present, it is unclear why casein stimulates the increase in serum insulin, whereas soy protein maintains normal levels of this hormone. There is evidence that soy protein decreases insulin secretion and increases hepatic insulin extraction (38). It is assumed that the amino acid pattern of each protein can stimulate the pancreatic release of insulin. A mechanism involving glutamine oxidation in ß-cells by glutamate dehydrogenase was proposed to demonstrate how a specific dietary amino acid pattern can modulate insulin secretion(39); however, more studies at the molecular level are required to understand the basis for the stimulation of insulin secretion by amino acids. We are currently studying the differences in the pattern of gene expression in pancreatic ß-cells; this may help explain the role of soy protein in preventing the elevation of serum insulin concentration.
On the other hand, the mechanisms by which the ingestion of soy protein reduces serum and hepatic cholesterol are not clear. Our results showed that there is a greater abundance of LDL receptors and HMG-CoA reductase mRNA in rats fed the soy protein diet than in those fed the casein diet. Furthermore, we observed that low hepatic cholesterol concentrations were associated with a greater abundance of LDL receptors and HMG-CoA reductase mRNA. Thus, there is an induction or a repression of genes involved in the synthesis and utilization of cholesterol, depending of the intracellular cholesterol concentration as previously described (9). The reduction in serum cholesterol is associated with a stimulation of bile acid synthesis, possibly through the induction of the enzyme CYP7A1, the rate-limiting step in the biosynthesis of bile acids (40). In addition, the low serum cholesterol concentrations observed in rats fed the soy protein diet might be due to the reduction of lipogenesis. Thus, the reduced biosynthesis of fatty acids in turn will reduce the production of VLDL particles, thus limiting the formation of LDL particles and resulting in low serum triglycerides and cholesterol concentrations. At the present time, we are studying the effect of soy protein on the synthesis and enterohepatic transport of bile acids.
Our results indicate that the regulation of hepatic lipid synthesis and deposition, mainly triglycerides, is associated with the type of dietary protein consumed. This regulation likely occurs indirectly via insulin through SREBP-1, and this will depend of the type of protein consumed. Nonetheless, more studies are warranted to determine whether the reduction in cholesterol concentration is a direct or an indirect effect of the soy protein.
| FOOTNOTES |
|---|
3 Abbreviations used: CYP7A1, 7-
hydroxylase; DTT, dithiothreitol; FAS, fatty acid synthase; HF, high fat; HMG-CoA, hydroxymethylglutaryl-CoA; PVDF, polyvinylidene difluoride; SREBP, sterol regulatory element binding protein. ![]()
Manuscript received 9 September 2003. Initial review completed 6 October 2003. Revision accepted 18 November 2003.
| LITERATURE CITED |
|---|
|
|
|---|
1. Bakhit, R. M., Klein, B. P., Essex-Sorlie, D., Ham, J. O., Erdman, J. W. & Potter, S. M. (1994) Intake of 25 g of soybean protein with or without soybean fiber alters plasma lipids in men with elevated cholesterol concentrations. J. Nutr. 124:213-222.
2. Carroll, K. K. & Kurowska, E. M. (1995) Soy consumption and cholesterol reduction: review of animal and human studies. J. Nutr. 125:594S-597S.
3. Anderson, J. W., Johnstone, B. M. & Cook-Newell, M. E. (1995) Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 333:276-282.
4. Lichtenstein, A. H. (2001) Got soy?. Am. J. Clin. Nutr. 73:667-668.
5. Young, V. R. (1991) Soy protein in relation to human protein and amino acid nutrition. J. Am. Diet. Assoc. 91:828-835.[Medline]
6. Torun, B., Viteri, F. E. & Young, V. R. (1981) Nutritional role of soya protein for humans. J. Am. Oil Chem. Soc. 58:400-406.
7. Potter, S. M. (1995) Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J. Nutr. 125:606S-611S.
8. Brown, M. S. & Goldstein, J. L. (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340.[Medline]
9. Horton, J. D., Goldstein, J. L. & Brown, M. S. (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 109:1125-1131.[Medline]
10. Yokoyama, C., Wang, X., Briggs, M. R., Admon, A., Wu, J., Hua, X., Goldstein, J. L. & Brown, M. S. (1993) SREBP-1, a basic helix-loop-helix leucine zipper protein that controls transcription of the LDL receptor gene. Cell 75:187-197.[Medline]
11. Hua, X., Yokoyama, C., Wu, J., Briggs, M. R., Brown, M. S., Goldstein, J. L. & Wang, X. (1993) SREBP-2 a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. Sci. U.S.A. 90:11603-11607.
12. Shimomura, I., Shimano, H., Horton, J. D., Goldstein, J. L. & Brown, M. S. (1997) Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cels. J. Clin. Investig. 99:838-845.[Medline]
13. Horton, J. D., Shimomura, I., Brown, M. S., Hammer, R. E., Goldstein, J. L. & Shimano, H. (1998) Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J. Clin. Investig. :1998.
14. Shimano, H., Yahagi, N., Amemiya-Kudo, M., Hasty, A. H., Osuga, J., Tamura, Y., Shionoiri, F., Iizuka, Y., Ohashi, K., Harada, K., Gotoda, T., Ishibashi, S. & Yamada, N. (1999) Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274:35832-35839.
15. Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S. & Goldstein, J. L. (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Mol. Cell. Biol. 19:3760-3768.
16. Matsuda, M., Korn, B. S., Hammer, R. E., Young-Ah, M., Komuro, R., Horton, J. D., Goldstein, J. L., Brown, M. S. & Shimomura, I. (2001) SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 15:1206-1216.
17. Tovar, A. R., Murguía, F., Cruz, C., Hernández-Pando, R., Aguilar-Salinas, C. A., Pedraza-Chaverri, J., Correa-Rotter, R. & Torres, N. (2002) A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome. J. Nutr. 132:2562-2569.
18. Tovar, A. R., Ascencio, C. & Torres, N. (2002) Soy protein, casein, and zein regulate histidase gene expression by modulating serum glucagon. Am. J. Physiol. 283:E1016-E1022.
19. Mezei, O., Banz, W. J., Steger, R. W., Peluso, M. R., Winters, T. A. & Shay, N. (2003) Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J. Nutr. 133:1238-1243.
20. Sheng, E., Otani, H., Brown, M. S. & Goldstein, J. L. (1995) Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc. Natl. Acad. Sci. U.S.A. 92:935-938.
21. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
22. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 227:680-685.[Medline]
23. Chomczynski, P. & Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.[Medline]
24. Folch, J., Lees, M. & Sloane-Stanley, G. H. (1957) A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:497-509.
25. Haney, P., Raefsky, E. C., Caliendo, A. & Patel, M. (1986) Precocious induction of hepatic glucokinase and malic enzyme in artificially reared rat pups fed a high-carbohydrate diet. Arch. Biochem. Biophys. 244:787-794.[Medline]
26. Hsu, R. Y. & Lardy, H. A. (1969) Malic enzyme. Methods Enzymol. 13:230-235.
27. Foretz, M., Guichard, C., Ferré, P. & Foufelle, F. (1999) Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl. Acad. Sci. U.S.A. 96:12737-12742.
28. Shimomura, I., Hammer, R. E., Richardson, J. A., Ikemoto, S., Bashmakov, Y., Goldstein, J. L. & Brown, M. S. (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 12:3182-3194.
29. Shimomura, I., Bashmakov, Y. & Horton, J. D. (1999) Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274:30028-30032.
30. Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Memiya-Kudo, M., Tomita, S. & Okazaki, H., et al (2002) Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers, but not obesity of insulin resistance in Lepob/Lepob mice. J. Biol. Chem. 277:19353-19367.
31. Morris, K., Wang, Y., Kim, S. & Moustaid-Moussa, N. (2001) Dietary and hormonal regulation of the mammalian fatty acid synthase gene. Moustaid-Moussa, N. Berdanier, C. D. eds. Nutrient-Gene Interactions in Health and Disease 2001 CRC Press Boca Raton, FL. .
32. Field, F. J., Born, E., Murthy, S. & Mathur, S. N. (2002) Polyunsaturated fatty acids decrease the expression of sterol regulatory element-binding protein-1 in CaCo-2 cells: effect on fatty acid synthesis and triacylglycerol transport. Biochem. J. 368:855-864.[Medline]
33. Lee, Y., Wang, M.-Y., Kakuma, T., Wang, Z.-W., Babcock, E., McCorkle, K., Higa, M., Zhou, Y.-T. & Unger, R. H. (2001) Liporegulation in diet-induced obesity. J. Biol. Chem. 276:5629-5635.
34. Unger, R. H. (2002) Lipotoxic diseases. Annu. Rev. Med. 53:319-336.[Medline]
35. Unger, R. H. & Orci, L. (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15:312-321.
36. Reaven, G. M. (1993) Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu. Rev. Med. 44:121-131.[Medline]
37. Burant, C. F., Sreenan, S., Hirano, K.-I., Tai, T.-A.C., Lohmiller, J., Lukens, J., Davison, N. O., Ross, S. & Graves, R. A. (1997) Troglitazone action is independent of adipose tissue. J. Clin. Investig. 100:2900-2908.[Medline]
38. Lavigne, C., Marette, A. & Jacques, H. (2000) Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats. Am. J. Physiol. 278:E491-E500.
39. Gao, Z.-Y., Li, G., Najafi, H., Wolf, B. A. & Matschinsky, F. M. (1999) Glucose regulation of glutaminolysis and its role in insulin secretion. Diabetes 47:1535-1542.
40. Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J. & Mangelsdorf, D. J. (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6:507-515.[Medline]
41. Rogers, Q. R. & Harper, A. E. (1965) Amino acid diets and maximal growth in the rat. J. Nutr. 87:267-273.
This article has been cited by other articles:
![]() |
C. W. Xiao Health Effects of Soy Protein and Isoflavones in Humans J. Nutr., June 1, 2008; 138(6): 1244S - 1249S. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Torre-Villalvazo, A. R. Tovar, V. E. Ramos-Barragan, M. A. Cerbon-Cervantes, and N. Torres Soy Protein Ameliorates Metabolic Abnormalities in Liver and Adipose Tissue of Rats Fed a High Fat Diet J. Nutr., March 1, 2008; 138(3): 462 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Noriega-Lopez, A. R. Tovar, M. Gonzalez-Granillo, R. Hernandez-Pando, B. Escalante, P. Santillan-Doherty, and N. Torres Pancreatic Insulin Secretion in Rats Fed a Soy Protein High Fat Diet Depends on the Interaction between the Amino Acid Pattern and Isoflavones J. Biol. Chem., July 13, 2007; 282(28): 20657 - 20666. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Xiao, J. Mei, W. Huang, C. Wood, M. R. L'Abbe, G. S. Gilani, G. M. Cooke, and I. H. Curran Dietary Soy Protein Isolate Modifies Hepatic Retinoic Acid Receptor-{beta} Proteins and Inhibits Their DNA Binding Activity in Rats J. Nutr., January 1, 2007; 137(1): 1 - 6. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Tovar, I. Torre-Villalvazo, M. Ochoa, A. L. Elias, V. Ortiz, C. A. Aguilar-Salinas, and N. Torres Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats J. Lipid Res., September 1, 2005; 46(9): 1823 - 1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Huang, C. Wood, M. R. L'Abbe, G. S. Gilani, K. A. Cockell, and C. W. Xiao Soy Protein Isolate Increases Hepatic Thyroid Hormone Receptor Content and Inhibits Its Binding to Target Genes in Rats J. Nutr., July 1, 2005; 135(7): 1631 - 1635. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Mullen, R. M. Brown, T. F. Osborne, and N. F. Shay Soy Isoflavones Affect Sterol Regulatory Element Binding Proteins (SREBPs) and SREBP-Regulated Genes in HepG2 Cells J. Nutr., November 1, 2004; 134(11): 2942 - 2947. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||